- Patents and allowances extend exclusivity for investigational Triple-Negative Breast Cancer therapy to 2040
- Underscores strength of proprietary PatternDE™ discovery platform
REDMOND, Wash., Oct. 13, 2025 (GLOBE NEWSWIRE) — Pattern…

REDMOND, Wash., Oct. 13, 2025 (GLOBE NEWSWIRE) — Pattern…